// App-Quantinova.ai

: Respiratory microbiology outcomes from an observational study of ivacaftor in people with cystic fibrosis and non-G551D gating mutations (VOCAL)

Researchers

Presenter

  • Carlo Castellani

Principal Investigators

  • Nicholas J. Simmonds

  • Carla Colombo

  • Nils Kinnman

  • Cynthia Desouza

  • Teja Thorat

  • Marci Chew

  • Keval Chandarana

  • Kors Van Der Ent

Medical Centers

  • NICU, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Universita degli Studi di Milano, Milan, Italy

  • Department of Respiratory Medicine, University Medical Centre Utrecht, Utrecht, Netherlands,

  • Vertex Pharmaceuticals Incorporated, Boston, United States of America

  • Cystic Fibrosis Centre, IRCCS Istituto Giannina Gaslini, Genoa, Italy

  • Adult Cystic Fibrosis Centre, Royal Brompton Hospital and Imperial College London, London, United Kingdom

Locations

  • United States

  • Italy

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Cystic Fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Ivacaftor

Outcome

  • N/A

Study Design

  • Observational

Phase

  • IV

Study Id's

  • NCT02445053

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved